Open Access

High TNF‑α and/or p38MAPK expression predicts a favourable prognosis in patients with T1N0M0 hepatocellular carcinoma: An immunohistochemical study

Corrigendum in: /10.3892/ol.2019.10781

  • Authors:
    • Mao Zhang
    • Jie Hu
    • Haoran Li
    • Shun Zhang
    • Weiyu Hu
    • Liqun Wu
    • Bing Han
  • View Affiliations

  • Published online on: March 27, 2019     https://doi.org/10.3892/ol.2019.10193
  • Pages: 4948-4956
  • Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Tumour necrosis factor α (TNF‑α) and p38 mitogen‑activated protein kinase (p38MAPK) serve an important role in regulating tumour cell apoptosis. However, a limited number of studies have investigated the predictive value of both TNF‑α and p38MAPK in hepatocellular carcinoma (HCC). An integrated bioinformatics analysis was initially performed using two datasets available from the Oncomine™ database to determine the association between TNF‑α and/or p38MAPK expression and prognosis of patients with HCC. Subsequently, TNF‑α and p38MAPK expression in tissue samples from 83 patients with HCC classified as T1N0M0, using the Tumour‑Node‑Metastasis (TNM) staging system, was investigated using immunohistochemistry. The associations between clinicopathological characteristics and different TNF‑α and p38MAPK expression levels in HCC were investigated using the χ2 test. Kaplan‑Meier and Cox univariate/multivariate survival analyses were performed to explore the predictive significance of TNF‑α and/or p38MAPK expression in patients with HCC. Using the Oncomine™ database, it was revealed that TNF‑α and/or p38MAPK expression was not significantly associated with overall survival (OS) or disease‑free survival (DFS) rates; however, TNF‑α and p38MAPK expression levels were positively associated (P<0.05), and high p38MAPK expression was significantly associated with low aspartate aminotransferase levels (P<0.05). Compared with low expression levels of TNF‑α and p38MAPK together, high expression of TNF‑α alone, p38MAPK alone and TNF‑α and p38MAPK together were significantly associated with improved OS and DFS rates (P<0.05). Additionally, multivariate Cox regression models suggested that high expression levels of TNF‑α alone, p38MAPK alone, or TNF‑α and p38MAPK together in the HCC microenvironment were independent predictive factors for OS and DFS rates (P<0.05). Patients with T1N0M0 HCC with high TNF‑α and/or p38MAPK expression had a significantly lower risk of recurrence and mortality compared with patients with low TNF‑α and p38MAPK expression. Consequently, TNF‑α and p38MAPK could serve as predictive biomarkers or potential therapeutic targets for T1N0M0 HCC treatment.
View Figures
View References

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Zhang, M., Hu, J., Li, H., Zhang, S., Hu, W., Wu, L., & Han, B. (2019). High TNF‑α and/or p38MAPK expression predicts a favourable prognosis in patients with T1N0M0 hepatocellular carcinoma: An immunohistochemical study Corrigendum in /10.3892/ol.2019.10781. Oncology Letters, 17, 4948-4956. https://doi.org/10.3892/ol.2019.10193
MLA
Zhang, M., Hu, J., Li, H., Zhang, S., Hu, W., Wu, L., Han, B."High TNF‑α and/or p38MAPK expression predicts a favourable prognosis in patients with T1N0M0 hepatocellular carcinoma: An immunohistochemical study Corrigendum in /10.3892/ol.2019.10781". Oncology Letters 17.6 (2019): 4948-4956.
Chicago
Zhang, M., Hu, J., Li, H., Zhang, S., Hu, W., Wu, L., Han, B."High TNF‑α and/or p38MAPK expression predicts a favourable prognosis in patients with T1N0M0 hepatocellular carcinoma: An immunohistochemical study Corrigendum in /10.3892/ol.2019.10781". Oncology Letters 17, no. 6 (2019): 4948-4956. https://doi.org/10.3892/ol.2019.10193